Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vicriviroc. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 known ✓ | P51681 | 20/20 | 0.91 |
| ▸ | CHRM2 | P08172 | 16/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.77 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vicriviroc SCHEMBL4447817 | 0.96 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| Vicriviroc SCHEMBL15375740 | 0.96 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| Vicriviroc SCHEMBL4638191 | 0.96 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| Vicriviroc SCHEMBL118885 | 0.96 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL19656878 | 0.91 | CCR5 (0.91) | CCR5CHRM2CHRM1CHRM3 | |
| Vicriviroc SCHEMBL3321008 | 0.91 | CCR5 (0.90) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL14032029 | 0.88 | CCR5 (0.85) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL13484306 | 0.88 | CCR5 (0.84) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL15199622 | 0.87 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL10073358 | 0.87 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109747-A1 | Conjugate Comprising an IL-2 Moiety | ASCENDIS PHARMA ONCOLOGY DIV A/S (DK) | 2026-04-23 | — | — | US | disclosed |
| EP-4709423-A1 | NOVEL CANCER TREATMENTS WITH IL-2 CONJUGATES | Ascendis Pharma Oncology Division A/S (DK) | 2026-03-18 | — | — | EP | disclosed |
| US-12428461-B2 | Treating cancer with a conjugate comprising an IL-2 moiety | Ascendis Pharma Oncology Division A/S (DK) | 2025-09-30 | — | — | US | disclosed |
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4556010-A2 | JAK INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF A VIRAL DISEASE CAUSED BY A CORONAVIRIDAE | Emory University (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-3906065-B1 | PRR AGONIST FOR USE IN THE TREATMENT OF CANCER | ASCENDIS PHARMA ONCOLOGY DIV A/S (DK) | 2025-04-30 | — | — | EP | disclosed |
| EP-3750544-B1 | JAK INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF A VIRAL DISEASE CAUSED BY A CORONAVIRIDAE | UNIV EMORY (US) | 2025-03-05 | — | — | EP | disclosed |
| US-20240415838-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2024-12-19 | — | — | US | disclosed |
| WO-2024231442-A1 | NOVEL CANCER TREATMENTS WITH IL-2 CONJUGATES | Ascendis Pharma Oncology Division A/S (DK) | 2024-11-14 | — | — | WO | disclosed |
| US-20240226108-A9 | TREATMENT OF BRAIN INJURIES | ASTON UNIVERSITY (GB) | 2024-07-11 | — | — | US | disclosed |
| WO-2022175640-A1 | TREATMENT OF BRAIN INJURIES | ASTON UNIVERSITY (GB) | 2022-08-25 | — | — | WO | disclosed |
| EP-3986479-A1 | ANTI-CTLA4 CONJUGATES | Ascendis Pharma Oncology Division A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986478-A1 | TYROSINE KINASE INHIBITOR CONJUGATES | Ascendis Pharma Oncology Division A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| US-20220110939-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | UNIV EMORY (US) | 2022-04-14 | — | — | US | disclosed |
| US-20220062273-A1 | CONJUGATES OF PATTERN RECOGNITION RECEPTOR AGONISTS | Ascendis Pharma Oncology Division A/S (DK) | 2022-03-03 | — | — | US | disclosed |
| WO-2022043493-A1 | GLYCOSYLATED IL-2 PROTEINS AND USES THEREOF | Ascendis Pharma Oncology Division A/S (DK) | 2022-03-03 | — | — | WO | disclosed |
| US-20220054478-A1 | MINIMIZATION OF SYSTEMIC INFLAMMATION | Ascendis Pharma Oncology Division A/S (DK) | 2022-02-24 | — | — | US | disclosed |
| US-20220054477-A1 | INDUCTION OF SUSTAINED LOCAL INFLAMMATION | Ascendis Pharma Oncology Division A/S (DK) | 2022-02-24 | — | — | US | disclosed |
| US-20220054476-A1 | SUSTAINED LOCAL DRUG LEVELS FOR INNATE IMMUNE AGONISTS | Ascendis Pharma Oncology Division A/S (DK) | 2022-02-24 | — | — | US | disclosed |
| US-20220040185-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054478-A1 | MINIMIZATION OF SYSTEMIC INFLAMMATION | CCR10, CXCL10, PROKR1 | CCR5 90/4885CHRM2 2832/4885CHRM1 3230/4885 |
| US-20260109747-A1 | Conjugate Comprising an IL-2 Moiety | IL2, IL2RA, ILF2 | CCR5 694/4885CHRM2 3680/4885CHRM1 4570/4885 |
| US-12428461-B2 | Treating cancer with a conjugate comprising an IL-2 moiety | IL2, IL2RA, ILF2 | CCR5 263/4885CHRM2 4001/4885CHRM1 4556/4885 |
| US-20220054476-A1 | SUSTAINED LOCAL DRUG LEVELS FOR INNATE IMMUNE AGONISTS | TLR3, TLR1, TLR9 | CCR5 512/4885CHRM2 3156/4885CHRM1 2932/4885 |
| US-20220110939-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | CCR5 357/4885CHRM2 4833/4885CHRM1 4588/4885 |
| US-20220054477-A1 | INDUCTION OF SUSTAINED LOCAL INFLAMMATION | GRPR, TLR3, TLR1 | CCR5 411/4885CHRM2 2253/4885CHRM1 2106/4885 |
| US-20240415838-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | CCR5 30/4885CHRM2 1445/4885CHRM1 903/4885 |
| US-20220062273-A1 | CONJUGATES OF PATTERN RECOGNITION RECEPTOR AGONISTS | LPAR1, TACR1, ADGRF1 | CCR5 503/4885CHRM2 315/4885CHRM1 243/4885 |
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | CCR5 224/4885CHRM2 4715/4885CHRM1 4309/4885 |
| US-20220040185-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | CCR5 30/4885CHRM2 1445/4885CHRM1 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.